BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL
Tweet Send to a Friend
Baird analyst Michael Ulz lowered the price target on BioMarin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
